Azenta Acquires UK Biocentre for £20.5M, Expands European Biorepository Capabilities
Azenta UK Ltd acquired UK Biocentre Limited for £20.5 million (plus up to £1.8 million in milestones), adding a UK facility that generated £15.3 million revenue in the year to September 2025. The transaction will dilute 2026 adjusted EBITDA margin by 35 bps and support 2027-28 revenue growth while broadening Azenta’s European biorepository capabilities.
1. Transaction Overview
Azenta UK Ltd completed the acquisition of UK Biocentre Limited for £20.5 million, plus up to £1.8 million in contingent consideration. UK Biocentre, founded in 2014, generated £15.3 million in revenue over the twelve months to September 2025 and will continue operating under its existing name as a European service hub.
2. Financial Impact
On a pro forma basis, the deal will dilute Azenta’s 2026 adjusted EBITDA margin by approximately 35 basis points. The transaction is expected to bolster organic revenue growth in 2027 and 2028 and contribute to margin expansion targets outlined at Azenta’s December Investor Day.
3. Strategic Rationale
The acquisition broadens Azenta’s European footprint by integrating UK Biocentre’s high-throughput sample management, storage services, and automation with Azenta’s Griesheim biorepository in Germany. Combined capabilities will support pharmaceutical, biotechnology, academic, and public health customers and facilitate deployment of the BioArc™ Ultra system later this year.